Differences in alpha 1-adrenoceptor subtype-mediated vasoconstriction by tyramine and nerve stimulation in canine splenic artery

J Pharmacol Sci. 2005 May;98(1):83-9. doi: 10.1254/jphs.fpj04057x. Epub 2005 May 12.

Abstract

This study was designed to clarify the alpha(1)-adrenoceptor subtypes mediating the vasoconstrictor response to tyramine in isolated and perfused canine splenic artery. It was shown that tyramine potentiated the nerve stimulation-induced second peaked vasoconstriction that was readily suppressed by prazosin treatment. A bolus injection of tyramine (0.01-0.3 micromol) caused a vasoconstriction in a dose-related manner. The tyramine-induced vasoconstriction was inhibited by WB 4101 (10 and 100 nM), an alpha(1A)-and alpha(1D)-adrenoceptor antagonist, in a concentration-related manner. Neither BMY 7378 (100 nM), a selective alpha(1D)-adrenoceptor antagonist, nor chloroethylclonidine (60 microM), an alpha(1B)- and alpha(1D)-adrenoceptor antagonist, affected the tyramine-induced response. The results indicate that the noradrenaline released by tyramine may diffuse to the extrajunctional cleft, and thus it activates the extrajunctional alpha(1A)-adrenoceptors, because nerve stimulation-evoked second peaked vasoconstrictions were markedly inhibited by chloroethylclonidine but not by WB 4101.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic Fibers / drug effects
  • Adrenergic Fibers / physiology*
  • Animals
  • Dogs
  • Dose-Response Relationship, Drug
  • Electric Stimulation / methods
  • Female
  • Male
  • Receptors, Adrenergic, alpha-1 / classification
  • Receptors, Adrenergic, alpha-1 / physiology*
  • Splenic Artery / drug effects*
  • Splenic Artery / physiology
  • Tyramine / pharmacology*
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology*

Substances

  • Receptors, Adrenergic, alpha-1
  • Tyramine